1. Phylogeny  
Fructosamine‐3‐kinase (FN3K) is highly conserved among vertebrates, being identified in mammals, birds, amphibians, and fishes, whereas close homologs are absent from yeasts and insects. Its evolutionary history suggests that FN3K likely emerged after a gene‐duplication event in which an ancestral FN3K‐related protein (FN3K-RP) gave rise to a divergent enzyme specialized for phosphorylating fructosamines (avemaria2015possibleroleof pages 1-2, conner2005somecluesas pages 1-3). FN3K shares distant relationships with small-molecule kinases such as the aminoglycoside phosphotransferases, as evidenced by sequence features and domain organization that place it within a distinct subgroup of the broader protein kinase-like (PKL) superfamily (beisswenger2001humanfructosamine3kinasepurification pages 1-2, delpierre2003fructosamine3kinasean pages 1-2). Phylogenetic studies based on sequence conservation further illustrate that while FN3K and FN3K-RP have approximately 65% sequence identity, they have evolved to acquire different substrate specificities and regulatory controls (avemaria2015possibleroleof pages 1-2, conner2005somecluesas pages 8-13).

2. Reaction Catalyzed  
FN3K catalyzes an ATP-dependent phosphorylation reaction that targets fructosamine adducts on glycated proteins. In this reaction, the enzyme transfers the γ-phosphate from ATP to the 3-hydroxyl group of the fructosamine residue (typically formed on lysine side chains) to yield ADP and a fructosamine-3-phosphate intermediate. This phosphorylated sugar adduct is inherently unstable under physiological conditions and spontaneously degrades into free lysine, inorganic phosphate, and 3-deoxyglucosone (3-DG) (beisswenger2001humanfructosamine3kinasepurification pages 2-4, delpierre2003fructosamine3kinasean pages 1-2).

3. Cofactor Requirements  
The catalytic activity of FN3K is dependent on ATP as a phosphate donor and requires divalent metal ions, most notably Mg²⁺, to coordinate and stabilize the nucleotide during phosphoryl transfer. This cofactor requirement is characteristic of kinases which utilize ATP during the phosphorylation of their substrates (beisswenger2001humanfructosamine3kinasepurification pages 1-2, tsai2006anewinhibitor pages 1-2).

4. Substrate Specificity  
FN3K exhibits a high degree of substrate specificity for protein-bound fructosamines. The enzyme preferentially phosphorylates fructoselysine residues in glycated proteins, showing markedly higher affinity for these adducts compared to free sugars. In addition, FN3K is also capable of phosphorylating other related sugar-amine adducts such as psicosamines and ribulosamines, although the primary substrate under physiological conditions is the fructoselysine residue on long-lived proteins like hemoglobin (avemaria2015possibleroleof pages 1-2, beeraka2021thetamingof pages 14-15, delpierre2003fructosamine3kinasean pages 1-2). This substrate selectivity ensures that FN3K effectively participates in the repair of proteins that have been modified by non-enzymatic glycation processes.

5. Structure  
FN3K is a monomeric protein consisting of 309 amino acids, with an approximate molecular weight of 35 kDa. Its structure is characterized by a central kinase domain that adopts the classical protein kinase-like fold, featuring a bilobal organization with an N-terminal lobe predominantly composed of β-sheets and a C-terminal lobe made mainly of α-helices (beisswenger2001humanfructosamine3kinasepurification pages 6-7, delpierrre2004identificationoffructosamine pages 1-1). Conserved catalytic residues such as Lys41, which is critical for ATP binding, along with Glu55 and Asp244—required for proper positioning of substrates and the divalent cation—are present in its active site (beisswenger2001humanfructosamine3kinasepurification pages 4-6, garg2025themolecularbasis pages 2-3). Moreover, FN3K harbors a conserved P-loop motif with repeated glycine residues that contributes not only to nucleotide binding but also appears to be strategically positioned relative to the substrate-binding pocket. Although no extended regulatory regions comparable to those found in classical eukaryotic protein kinases have been described, its overall topology is consistent with that of kinases adapted for small molecule substrates (beisswenger2001humanfructosamine3kinasepurification pages 1-2, fortpied2005plantribulosamineerythrulosamine3kinase pages 6-7). Structural modeling and limited crystallographic data confirm that the core kinase fold is maintained, and unique features such as a compact substrate-binding region tailor FN3K for its specialized deglycation function (garg2025themolecularbasis pages 8-10).

6. Regulation  
Regulation of FN3K occurs primarily at the level of enzymatic activity rather than through extensive post-translational modifications typically seen in multisite-regulated kinases. Variability in FN3K activity has been observed among tissues and is correlated with intracellular glucose concentrations, as tissues with long-lived proteins (e.g., erythrocytes, lens, brain) exhibit higher activity to counteract glycation (avemaria2015possibleroleof pages 1-2, dacunha2006increasedproteinglycation pages 6-7). Additionally, genetic polymorphisms in the FN3K gene have been shown to influence enzyme activity and, consequently, site-specific protein glycation, as seen by differences in glycation levels of hemoglobin in normoglycemic subjects (delpierre2006variabilityinerythrocyte pages 1-2, conner2005somecluesas pages 8-13). Although detailed post-translational regulation mechanisms (such as phosphorylation or ubiquitination of FN3K itself) are not extensively characterized in the current literature, the enzyme’s activity appears to be modulated by substrate accessibility and possibly by changes in cellular redox conditions as indirectly implicated by studies examining protein repair functions (beisswenger2001humanfructosamine3kinasepurification pages 2-4, tsai2006anewinhibitor pages 1-2).

7. Function  
FN3K functions as a protein repair enzyme by reversing non-enzymatic glycation modifications that occur during the Maillard reaction. By phosphorylating fructoselysine residues on glycated proteins, FN3K generates fructoselysine-3-phosphate, an unstable intermediate that spontaneously degrades to regenerate the unmodified lysine residue along with the production of 3-deoxyglucosone (3-DG) and inorganic phosphate (beisswenger2001humanfructosamine3kinasepurification pages 2-4, delpierre2003fructosamine3kinasean pages 1-2). This deglycation process is especially important in erythrocytes, where proteins cannot be newly synthesized during the 120-day lifespan of the cell, thereby necessitating a repair mechanism to maintain protein function (avemaria2015possibleroleof pages 1-2, dacunha2006increasedproteinglycation pages 6-7). In addition to its role in protein repair, FN3K has been implicated in the cellular response to oxidative stress. By reversing glycation on key regulatory proteins such as NRF2, FN3K helps to maintain antioxidant responses, which are critical for redox homeostasis in cells (beeraka2021thetamingof pages 12-14, beisswenger2001humanfructosamine3kinasepurification pages 2-4). The enzyme is expressed ubiquitously, with appreciable levels in tissues that are particularly susceptible to glycation damage due to high intracellular glucose concentration, indicating a protective role especially in diabetic conditions (dacunha2006increasedproteinglycation pages 7-8, conner2005somecluesas pages 1-3).

8. Other Comments  
Several studies have explored the potential pharmacological modulation of FN3K activity. For example, substrate analogs such as 1-deoxy-1-morpholinofructose (DMF) have been used to competitively inhibit FN3K, thereby leading to increased glycation levels, which underscores the enzyme’s critical role in protein maintenance (tsai2006anewinhibitor pages 1-2, szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 1-2). FN3K has also been investigated with regard to its involvement in diabetic complications, as aberrant glycation and impaired deglycation are associated with increased formation of advanced glycation end-products (AGEs) that contribute to tissue damage in diabetes (avemaria2015possibleroleof pages 1-2, szwergold2011thephysiologicalsubstrates pages 1-2). Given these disease associations, FN3K represents a potential therapeutic target for interventions aimed at mitigating glycation-induced cellular dysfunction, although the development of highly specific inhibitors remains a challenge due to the enzyme’s unique substrate selectivity and regulatory properties (tsai2006anewinhibitor pages 1-2).

9. References  
1. Avemaria, et al. “Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients.” Clinical Chemistry and Laboratory Medicine, 53:1315-1320, Aug 2015. (avemaria2015possibleroleof pages 1-2)  
2. Beeraka, et al. “The taming of nuclear factor erythroid-2-related factor-2 (Nrf2) deglycation by fructosamine-3-kinase (FN3K)-inhibitors—a novel strategy to combat cancers.” Cancers, 13:281, Jan 2021. (beeraka2021thetamingof pages 12-14; beeraka2021thetamingof pages 14-15)  
3. Beisswenger, P.J., Szwergold, B.S., & Howell, S. “Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo.” Diabetes, 50(9):2139-47, Sep 2001. (beisswenger2001humanfructosamine3kinasepurification pages 1-2, pages 2-4, pages 4-6, pages 6-7)  
4. Conner, J.R., Beisswenger, P.J., & Szwergold, B.S. “Some clues as to the regulation, expression, function, and distribution of fructosamine‐3‐kinase and fructosamine‐3‐kinase‐related protein.” Annals of the New York Academy of Sciences, 1043:824-836, Jun 2005. (conner2005somecluesas pages 1-3, pages 8-13)  
5. Veiga-da-Cunha, M., et al. “Increased protein glycation in fructosamine 3-kinase-deficient mice.” The Biochemical journal, 399(2):257-264, Oct 2006. (dacunha2006increasedproteinglycation pages 6-7, pages 7-8)  
6. Delpierre, G. & Van Schaftingen, E. “Fructosamine 3-kinase, an enzyme involved in protein deglycation.” Biochemical Society Transactions, 31:1354-1357, Dec 2003. (delpierre2003fructosamine3kinasean pages 1-2, pages 2-3)  
7. Delpierre, G., et al. “Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites.” Diabetes & Metabolism, 32:31-39, Feb 2006. (delpierre2006variabilityinerythrocyte pages 1-2)  
8. Delpierrre, G., et al. “Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin.” Journal of Biological Chemistry, 279:27613-27620, Jun 2004. (delpierrre2004identificationoffructosamine pages 1-1)  
9. Delplanque, J., et al. “Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein.” Journal of Biological Chemistry, 279:46606-46613, Nov 2004. (delplanque2004tissuedistributionand pages 1-1, pages 3-4)  
10. Fortpied, J., et al. “Plant ribulosamine/erythrulosamine 3-kinase, a putative protein-repair enzyme.” Biochemical Journal, 388:795-802, Jun 2005. (fortpied2005plantribulosamineerythrulosamine3kinase pages 6-7)  
11. Garg, A., et al. “The molecular basis of human FN3K mediated phosphorylation of glycated substrates.” Nature Communications, Jan 2025. (garg2025themolecularbasis pages 1-2, pages 2-3, pages 8-10, pages 8-8)  
12. Payne, L.S., et al. “Mapping of the ATP-binding domain of human fructosamine 3-kinase-related protein by affinity labelling with 5′-[p-(fluorosulfonyl)benzoyl]adenosine.” Biochemical Journal, 416:281-288, Nov 2008. (payne2008mappingofthe pages 1-2)  
13. Szwergold, B. & Loomes, K.M. “Fructosamine-3-kinase-related-protein phosphorylates glucitolamines on the C-4 hydroxyl: novel substrate specificity of an enigmatic enzyme.” Biochemical and Biophysical Research Communications, 361(4):870-5, Oct 2007. (szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 1-2)  
14. Szwergold, B.S., et al. “The physiological substrates of fructosamine-3-kinase-related-protein...” Medical Hypotheses, 77:739-744, Nov 2011. (szwergold2011thephysiologicalsubstrates pages 1-2)  
15. Tsai, H.J., et al. “A new inhibitor for fructosamine 3-kinase (amadorase).” Drug Development Research, 67:448-455, May 2006. (tsai2006anewinhibitor pages 1-2)

References

1. (avemaria2015possibleroleof pages 1-2): Francesca Avemaria, Paola Carrera, Annunziata Lapolla, Giovanni Sartore, Nino Cristiano Chilelli, Renata Paleari, Alessandro Ambrosi, Maurizio Ferrari, and Andrea Mosca. Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients. Clinical Chemistry and Laboratory Medicine (CCLM), 53:1315-1320, Aug 2015. URL: https://doi.org/10.1515/cclm-2015-0207, doi:10.1515/cclm-2015-0207. This article has 23 citations.

2. (beeraka2021thetamingof pages 12-14): Narasimha M. Beeraka, Venugopal R. Bovilla, Shalini H. Doreswamy, Sujatha Puttalingaiah, Asha Srinivasan, and SubbaRao V. Madhunapantula. The taming of nuclear factor erythroid-2-related factor-2 (nrf2) deglycation by fructosamine-3-kinase (fn3k)-inhibitors-a novel strategy to combat cancers. Cancers, 13:281, Jan 2021. URL: https://doi.org/10.3390/cancers13020281, doi:10.3390/cancers13020281. This article has 25 citations and is from a peer-reviewed journal.

3. (beeraka2021thetamingof pages 14-15): Narasimha M. Beeraka, Venugopal R. Bovilla, Shalini H. Doreswamy, Sujatha Puttalingaiah, Asha Srinivasan, and SubbaRao V. Madhunapantula. The taming of nuclear factor erythroid-2-related factor-2 (nrf2) deglycation by fructosamine-3-kinase (fn3k)-inhibitors-a novel strategy to combat cancers. Cancers, 13:281, Jan 2021. URL: https://doi.org/10.3390/cancers13020281, doi:10.3390/cancers13020281. This article has 25 citations and is from a peer-reviewed journal.

4. (beisswenger2001humanfructosamine3kinasepurification pages 1-2): PJ Beisswenger BS Szwergold, S Howell. Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes, 50 9:2139-47, Sep 2001. URL: https://doi.org/10.2337/diabetes.50.9.2139, doi:10.2337/diabetes.50.9.2139. This article has 211 citations.

5. (beisswenger2001humanfructosamine3kinasepurification pages 2-4): PJ Beisswenger BS Szwergold, S Howell. Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes, 50 9:2139-47, Sep 2001. URL: https://doi.org/10.2337/diabetes.50.9.2139, doi:10.2337/diabetes.50.9.2139. This article has 211 citations.

6. (beisswenger2001humanfructosamine3kinasepurification pages 4-6): PJ Beisswenger BS Szwergold, S Howell. Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes, 50 9:2139-47, Sep 2001. URL: https://doi.org/10.2337/diabetes.50.9.2139, doi:10.2337/diabetes.50.9.2139. This article has 211 citations.

7. (beisswenger2001humanfructosamine3kinasepurification pages 6-7): PJ Beisswenger BS Szwergold, S Howell. Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes, 50 9:2139-47, Sep 2001. URL: https://doi.org/10.2337/diabetes.50.9.2139, doi:10.2337/diabetes.50.9.2139. This article has 211 citations.

8. (conner2005somecluesas pages 1-3): JAMES R. CONNER, PAUL J. BEISSWENGER, and BENJAMIN S. SZWERGOLD. Some clues as to the regulation, expression, function, and distribution of fructosamine‐3‐kinase and fructosamine‐3‐kinase‐related protein. Annals of the New York Academy of Sciences, 1043:824-836, Jun 2005. URL: https://doi.org/10.1196/annals.1333.095, doi:10.1196/annals.1333.095. This article has 50 citations and is from a peer-reviewed journal.

9. (conner2005somecluesas pages 8-13): JAMES R. CONNER, PAUL J. BEISSWENGER, and BENJAMIN S. SZWERGOLD. Some clues as to the regulation, expression, function, and distribution of fructosamine‐3‐kinase and fructosamine‐3‐kinase‐related protein. Annals of the New York Academy of Sciences, 1043:824-836, Jun 2005. URL: https://doi.org/10.1196/annals.1333.095, doi:10.1196/annals.1333.095. This article has 50 citations and is from a peer-reviewed journal.

10. (dacunha2006increasedproteinglycation pages 6-7): Maria VEIGA da-Cunha, Patrick Jacquemin, Ghislain Delpierre, Catherine Godfraind, Ivan Théate, Didier Vertommen, Frédéric Clotman, Frédéric Lemaigre, Olivier Devuyst, and Emile Van Schaftingen. Increased protein glycation in fructosamine 3-kinase-deficient mice. The Biochemical journal, 399 2:257-64, Oct 2006. URL: https://doi.org/10.1042/bj20060684, doi:10.1042/bj20060684. This article has 82 citations.

11. (dacunha2006increasedproteinglycation pages 7-8): Maria VEIGA da-Cunha, Patrick Jacquemin, Ghislain Delpierre, Catherine Godfraind, Ivan Théate, Didier Vertommen, Frédéric Clotman, Frédéric Lemaigre, Olivier Devuyst, and Emile Van Schaftingen. Increased protein glycation in fructosamine 3-kinase-deficient mice. The Biochemical journal, 399 2:257-64, Oct 2006. URL: https://doi.org/10.1042/bj20060684, doi:10.1042/bj20060684. This article has 82 citations.

12. (delpierre2003fructosamine3kinasean pages 1-2): G. Delpierre and E. Van Schaftingen. Fructosamine 3-kinase, an enzyme involved in protein deglycation. Biochemical Society Transactions, 31:1354-1357, Dec 2003. URL: https://doi.org/10.1042/bst0311354, doi:10.1042/bst0311354. This article has 48 citations and is from a peer-reviewed journal.

13. (delpierre2006variabilityinerythrocyte pages 1-2): G Delpierre, M Veiga-da-Cunha, D Vertommen, M Buysschaert, and E Van Schaftingen. Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the fn3k gene and impacts on haemoglobin glycation at specific sites. Diabetes &amp; Metabolism, 32:31-39, Feb 2006. URL: https://doi.org/10.1016/s1262-3636(07)70244-6, doi:10.1016/s1262-3636(07)70244-6. This article has 62 citations.

14. (delpierrre2004identificationoffructosamine pages 1-1): Ghislain Delpierrre, Didier Vertommen, David Communi, Mark H. Rider, and Emile Van Schaftingen. Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. Journal of Biological Chemistry, 279:27613-27620, Jun 2004. URL: https://doi.org/10.1074/jbc.m402091200, doi:10.1074/jbc.m402091200. This article has 102 citations and is from a domain leading peer-reviewed journal.

15. (delplanque2004tissuedistributionand pages 1-1): Jérôme Delplanque, Ghislain Delpierre, Fred R. Opperdoes, and Emile Van Schaftingen. Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. Journal of Biological Chemistry, 279:46606-46613, Nov 2004. URL: https://doi.org/10.1074/jbc.m407678200, doi:10.1074/jbc.m407678200. This article has 67 citations and is from a domain leading peer-reviewed journal.

16. (fortpied2005plantribulosamineerythrulosamine3kinase pages 6-7): Juliette FORTPIED, Rita GEMAYEL, Vincent STROOBANT, and Emile van SCHAFTINGEN. Plant ribulosamine/erythrulosamine 3-kinase, a putative protein-repair enzyme. Biochemical Journal, 388:795-802, Jun 2005. URL: https://doi.org/10.1042/bj20041976, doi:10.1042/bj20041976. This article has 40 citations and is from a domain leading peer-reviewed journal.

17. (garg2025themolecularbasis pages 1-2): Ankur Garg, Kin Fan On, Yang Xiao, Elad Elkayam, Paolo Cifani, Yael David, and Leemor Joshua-Tor. The molecular basis of human fn3k mediated phosphorylation of glycated substrates. Nature Communications, Jan 2025. URL: https://doi.org/10.1038/s41467-025-56207-z, doi:10.1038/s41467-025-56207-z. This article has 1 citations and is from a highest quality peer-reviewed journal.

18. (garg2025themolecularbasis pages 2-3): Ankur Garg, Kin Fan On, Yang Xiao, Elad Elkayam, Paolo Cifani, Yael David, and Leemor Joshua-Tor. The molecular basis of human fn3k mediated phosphorylation of glycated substrates. Nature Communications, Jan 2025. URL: https://doi.org/10.1038/s41467-025-56207-z, doi:10.1038/s41467-025-56207-z. This article has 1 citations and is from a highest quality peer-reviewed journal.

19. (garg2025themolecularbasis pages 8-10): Ankur Garg, Kin Fan On, Yang Xiao, Elad Elkayam, Paolo Cifani, Yael David, and Leemor Joshua-Tor. The molecular basis of human fn3k mediated phosphorylation of glycated substrates. Nature Communications, Jan 2025. URL: https://doi.org/10.1038/s41467-025-56207-z, doi:10.1038/s41467-025-56207-z. This article has 1 citations and is from a highest quality peer-reviewed journal.

20. (payne2008mappingofthe pages 1-2): Leo S. Payne, Peter M. Brown, Martin Middleditch, Edward Baker, Garth J. S. Cooper, and Kerry M. Loomes. Mapping of the atp-binding domain of human fructosamine 3-kinase-related protein by affinity labelling with 5′-[<i>p</i>-(fluorosulfonyl)benzoyl]adenosine. Biochemical Journal, 416:281-288, Nov 2008. URL: https://doi.org/10.1042/bj20080389, doi:10.1042/bj20080389. This article has 14 citations and is from a domain leading peer-reviewed journal.

21. (szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 1-2): Benjamin Szwergold, Yefim Manevich, Leo Payne, and Kerry Loomes. Fructosamine-3-kinase-related-protein phosphorylates glucitolamines on the c-4 hydroxyl: novel substrate specificity of an enigmatic enzyme. Biochemical and biophysical research communications, 361 4:870-5, Oct 2007. URL: https://doi.org/10.1016/j.bbrc.2007.07.127, doi:10.1016/j.bbrc.2007.07.127. This article has 11 citations and is from a peer-reviewed journal.

22. (szwergold2011thephysiologicalsubstrates pages 1-2): Benjamin S. Szwergold, Richard D. Bunker, and Kerry M. Loomes. The physiological substrates of fructosamine-3-kinase-related-protein (fn3krp) are intermediates of nonenzymatic reactions between biological amines and ketose sugars (fructation products). Medical Hypotheses, 77:739-744, Nov 2011. URL: https://doi.org/10.1016/j.mehy.2011.07.027, doi:10.1016/j.mehy.2011.07.027. This article has 10 citations and is from a peer-reviewed journal.

23. (tsai2006anewinhibitor pages 1-2): Henry J. Tsai, Shan‐Yen Chou, Frank Kappler, Michael L. Schwartz, and Annette M. Tobia. A new inhibitor for fructosamine 3‐kinase (amadorase). Drug Development Research, 67:448-455, May 2006. URL: https://doi.org/10.1002/ddr.20105, doi:10.1002/ddr.20105. This article has 8 citations and is from a peer-reviewed journal.